- Home
- LGIH vs MLTX Comparison
LGIH vs MLTX Comparison
Compare LGIH & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGIH
- MLTX
- Stock Information
- Founded
- LGIH 2003
- MLTX 2021
- Country
- LGIH United States
- MLTX Switzerland
- Employees
- LGIH N/A
- MLTX N/A
- Industry
- LGIH Homebuilding
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- LGIH Consumer Discretionary
- MLTX Health Care
- Exchange
- LGIH Nasdaq
- MLTX Nasdaq
- Market Cap
- LGIH 1.1B
- MLTX 904.7M
- IPO Year
- LGIH 2013
- MLTX N/A
- Fundamental
- Price
- LGIH $45.97
- MLTX $12.95
- Analyst Decision
- LGIH Hold
- MLTX Buy
- Analyst Count
- LGIH 5
- MLTX 9
- Target Price
- LGIH $71.13
- MLTX $36.78
- AVG Volume (30 Days)
- LGIH 390.8K
- MLTX 2.3M
- Earning Date
- LGIH 11-04-2025
- MLTX 11-05-2025
- Dividend Yield
- LGIH N/A
- MLTX N/A
- EPS Growth
- LGIH N/A
- MLTX N/A
- EPS
- LGIH 4.53
- MLTX N/A
- Revenue
- LGIH $1,788,933,000.00
- MLTX N/A
- Revenue This Year
- LGIH N/A
- MLTX N/A
- Revenue Next Year
- LGIH $15.95
- MLTX N/A
- P/E Ratio
- LGIH $10.12
- MLTX N/A
- Revenue Growth
- LGIH N/A
- MLTX N/A
- 52 Week Low
- LGIH $39.70
- MLTX $5.95
- 52 Week High
- LGIH $114.56
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- LGIH 47.37
- MLTX 45.54
- Support Level
- LGIH $45.32
- MLTX $12.21
- Resistance Level
- LGIH $49.86
- MLTX $13.07
- Average True Range (ATR)
- LGIH 2.50
- MLTX 0.70
- MACD
- LGIH 0.72
- MLTX 1.36
- Stochastic Oscillator
- LGIH 62.89
- MLTX 94.63
About LGIH LGI Homes Inc.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.